A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of ADSTEM Inj. for Moderate to Severe Subacute and Chronic Atopic Dermatitis Patients
Latest Information Update: 17 Feb 2026
At a glance
- Drugs Autologous stem cell therapy (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors EHL Bio
Most Recent Events
- 12 Feb 2026 Planned initiation date changed from 1 Jan 2026 to 1 Jun 2026.
- 04 Feb 2026 New trial record